Statin action favors normalization of the plasma lipidome in the atherogenic mixed dyslipidemia of MetS: potential relevance to statin-associated dysglycemia.
Identifieur interne : 002649 ( PubMed/Checkpoint ); précédent : 002648; suivant : 002650Statin action favors normalization of the plasma lipidome in the atherogenic mixed dyslipidemia of MetS: potential relevance to statin-associated dysglycemia.
Auteurs : Peter J. Meikle [Australie] ; Gerard Wong [Australie] ; Ricardo Tan [Australie] ; Philippe Giral [France] ; Paul Robillard [France] ; Alexina Orsoni [France] ; Neil Hounslow [Royaume-Uni] ; Dianna J. Magliano [Australie] ; Jonathan E. Shaw [Australie] ; Joanne E. Curran [États-Unis] ; John Blangero [États-Unis] ; Bronwyn A. Kingwell [Australie] ; M John Chapman [France]Source :
- Journal of lipid research [ 1539-7262 ] ; 2015.
Descripteurs français
- KwdFr :
- Adulte, Adulte d'âge moyen, Athérosclérose (sang), Athérosclérose (traitement médicamenteux), Cholestérol, Cholestérol HDL, Cholestérol LDL, Dyslipidémies (sang), Dyslipidémies (traitement médicamenteux), Femelle, Humains, Inhibiteurs de l'hydroxyméthylglutaryl-CoA réductase (usage thérapeutique), Lipoprotéines, Mâle, Sujet âgé, Syndrome métabolique X (sang), Syndrome métabolique X (traitement médicamenteux), Triglycéride, Troubles du métabolisme du glucose (), Troubles du métabolisme du glucose (sang).
- MESH :
- sang : Athérosclérose, Dyslipidémies, Syndrome métabolique X, Troubles du métabolisme du glucose.
- traitement médicamenteux : Athérosclérose, Dyslipidémies, Syndrome métabolique X.
- usage thérapeutique : Inhibiteurs de l'hydroxyméthylglutaryl-CoA réductase.
- Adulte, Adulte d'âge moyen, Cholestérol, Cholestérol HDL, Cholestérol LDL, Femelle, Humains, Lipoprotéines, Mâle, Sujet âgé, Triglycéride, Troubles du métabolisme du glucose.
English descriptors
- KwdEn :
- Adult, Aged, Atherosclerosis (blood), Atherosclerosis (drug therapy), Cholesterol, Cholesterol, HDL, Cholesterol, LDL, Dyslipidemias (blood), Dyslipidemias (drug therapy), Female, Glucose Metabolism Disorders (blood), Glucose Metabolism Disorders (chemically induced), Humans, Hydroxymethylglutaryl-CoA Reductase Inhibitors (therapeutic use), Lipoproteins, Male, Metabolic Syndrome X (blood), Metabolic Syndrome X (drug therapy), Middle Aged, Triglycerides.
- MESH :
- chemical , therapeutic use : Hydroxymethylglutaryl-CoA Reductase Inhibitors.
- chemical : Cholesterol, Cholesterol, HDL, Cholesterol, LDL, Lipoproteins, Triglycerides.
- blood : Atherosclerosis, Dyslipidemias, Glucose Metabolism Disorders, Metabolic Syndrome X.
- chemically induced : Glucose Metabolism Disorders.
- drug therapy : Atherosclerosis, Dyslipidemias, Metabolic Syndrome X.
- Adult, Aged, Female, Humans, Male, Middle Aged.
Abstract
The impact of statin treatment on the abnormal plasma lipidome of mixed dyslipidemic patients with metabolic syndrome (MetS), a group at increased risk of developing diabetes, was evaluated. Insulin-resistant hypertriglyceridemic hypertensive obese males (n = 12) displaying MetS were treated with pitavastatin (4 mg/day) for 180 days; healthy normolipidemic age-matched nonobese males (n = 12) acted as controls. Statin treatment substantially normalized triglyceride (-41%), remnant cholesterol (-55%), and LDL-cholesterol (-39%), with minor effect on HDL-cholesterol (+4%). Lipidomic analysis, normalized to nonHDL-cholesterol in order to probe statin-induced differences in molecular composition independently of reduction in plasma cholesterol, revealed increment in 132 of 138 lipid species that were subnormal at baseline and significantly shifted toward the control group on statin treatment. Increment in alkyl- and alkenylphospholipids (plasmalogens) was prominent, and consistent with significant statin-induced increase in plasma polyunsaturated fatty acid levels. Comparison of the statin-mediated lipidomic changes in MetS with the abnormal plasma lipidomic profile characteristic of prediabetes and T2D in the Australian Diabetes, Obesity, and Lifestyle Study and San Antonio Family Heart Study cohorts by hypergeometric analysis revealed a significant shift toward the lipid profile of controls, indicative of a marked trend toward a normolipidemic phenotype. Pitavastatin attenuated the abnormal plasma lipidome of MetS patients typical of prediabetes and T2D.
DOI: 10.1194/jlr.P061143
PubMed: 26486974
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:26486974Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Statin action favors normalization of the plasma lipidome in the atherogenic mixed dyslipidemia of MetS: potential relevance to statin-associated dysglycemia.</title><author><name sortKey="Meikle, Peter J" sort="Meikle, Peter J" uniqKey="Meikle P" first="Peter J" last="Meikle">Peter J. Meikle</name><affiliation wicri:level="3"><nlm:affiliation>Baker IDI Heart and Diabetes Institute, Melbourne, Australia peter.meikle@bakeridi.edu.au.</nlm:affiliation><country wicri:rule="url">Australie</country><wicri:regionArea>Baker IDI Heart and Diabetes Institute, Melbourne</wicri:regionArea><placeName><settlement type="city">Melbourne</settlement><region type="état">Victoria (État)</region></placeName></affiliation></author><author><name sortKey="Wong, Gerard" sort="Wong, Gerard" uniqKey="Wong G" first="Gerard" last="Wong">Gerard Wong</name><affiliation wicri:level="3"><nlm:affiliation>Baker IDI Heart and Diabetes Institute, Melbourne, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Baker IDI Heart and Diabetes Institute, Melbourne</wicri:regionArea><placeName><settlement type="city">Melbourne</settlement><region type="état">Victoria (État)</region></placeName></affiliation></author><author><name sortKey="Tan, Ricardo" sort="Tan, Ricardo" uniqKey="Tan R" first="Ricardo" last="Tan">Ricardo Tan</name><affiliation wicri:level="3"><nlm:affiliation>Baker IDI Heart and Diabetes Institute, Melbourne, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Baker IDI Heart and Diabetes Institute, Melbourne</wicri:regionArea><placeName><settlement type="city">Melbourne</settlement><region type="état">Victoria (État)</region></placeName></affiliation></author><author><name sortKey="Giral, Philippe" sort="Giral, Philippe" uniqKey="Giral P" first="Philippe" last="Giral">Philippe Giral</name><affiliation wicri:level="3"><nlm:affiliation>Dyslipidemia and Atherosclerosis Research Unit, INSERM UMR-S939, and University of Pierre and Marie Curie, Pitie-Salpetriere University Hospital, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Dyslipidemia and Atherosclerosis Research Unit, INSERM UMR-S939, and University of Pierre and Marie Curie, Pitie-Salpetriere University Hospital, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Robillard, Paul" sort="Robillard, Paul" uniqKey="Robillard P" first="Paul" last="Robillard">Paul Robillard</name><affiliation wicri:level="3"><nlm:affiliation>Dyslipidemia and Atherosclerosis Research Unit, INSERM UMR-S939, and University of Pierre and Marie Curie, Pitie-Salpetriere University Hospital, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Dyslipidemia and Atherosclerosis Research Unit, INSERM UMR-S939, and University of Pierre and Marie Curie, Pitie-Salpetriere University Hospital, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Orsoni, Alexina" sort="Orsoni, Alexina" uniqKey="Orsoni A" first="Alexina" last="Orsoni">Alexina Orsoni</name><affiliation wicri:level="3"><nlm:affiliation>Dyslipidemia and Atherosclerosis Research Unit, INSERM UMR-S939, and University of Pierre and Marie Curie, Pitie-Salpetriere University Hospital, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Dyslipidemia and Atherosclerosis Research Unit, INSERM UMR-S939, and University of Pierre and Marie Curie, Pitie-Salpetriere University Hospital, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Hounslow, Neil" sort="Hounslow, Neil" uniqKey="Hounslow N" first="Neil" last="Hounslow">Neil Hounslow</name><affiliation wicri:level="1"><nlm:affiliation>Kowa Research Europe Ltd., Wokingham, United Kingdom.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Kowa Research Europe Ltd., Wokingham</wicri:regionArea><wicri:noRegion>Wokingham</wicri:noRegion></affiliation></author><author><name sortKey="Magliano, Dianna J" sort="Magliano, Dianna J" uniqKey="Magliano D" first="Dianna J" last="Magliano">Dianna J. Magliano</name><affiliation wicri:level="3"><nlm:affiliation>Baker IDI Heart and Diabetes Institute, Melbourne, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Baker IDI Heart and Diabetes Institute, Melbourne</wicri:regionArea><placeName><settlement type="city">Melbourne</settlement><region type="état">Victoria (État)</region></placeName></affiliation></author><author><name sortKey="Shaw, Jonathan E" sort="Shaw, Jonathan E" uniqKey="Shaw J" first="Jonathan E" last="Shaw">Jonathan E. Shaw</name><affiliation wicri:level="3"><nlm:affiliation>Baker IDI Heart and Diabetes Institute, Melbourne, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Baker IDI Heart and Diabetes Institute, Melbourne</wicri:regionArea><placeName><settlement type="city">Melbourne</settlement><region type="état">Victoria (État)</region></placeName></affiliation></author><author><name sortKey="Curran, Joanne E" sort="Curran, Joanne E" uniqKey="Curran J" first="Joanne E" last="Curran">Joanne E. Curran</name><affiliation wicri:level="2"><nlm:affiliation>South Texas Diabetes and Obesity Institute, University of Texas Health Science Center at San Antonio, Harlingen, TX.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Texas</region></placeName><wicri:cityArea>South Texas Diabetes and Obesity Institute, University of Texas Health Science Center at San Antonio, Harlingen</wicri:cityArea></affiliation></author><author><name sortKey="Blangero, John" sort="Blangero, John" uniqKey="Blangero J" first="John" last="Blangero">John Blangero</name><affiliation wicri:level="2"><nlm:affiliation>South Texas Diabetes and Obesity Institute, University of Texas Health Science Center at San Antonio, Harlingen, TX.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Texas</region></placeName><wicri:cityArea>South Texas Diabetes and Obesity Institute, University of Texas Health Science Center at San Antonio, Harlingen</wicri:cityArea></affiliation></author><author><name sortKey="Kingwell, Bronwyn A" sort="Kingwell, Bronwyn A" uniqKey="Kingwell B" first="Bronwyn A" last="Kingwell">Bronwyn A. Kingwell</name><affiliation wicri:level="3"><nlm:affiliation>Baker IDI Heart and Diabetes Institute, Melbourne, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Baker IDI Heart and Diabetes Institute, Melbourne</wicri:regionArea><placeName><settlement type="city">Melbourne</settlement><region type="état">Victoria (État)</region></placeName></affiliation></author><author><name sortKey="Chapman, M John" sort="Chapman, M John" uniqKey="Chapman M" first="M John" last="Chapman">M John Chapman</name><affiliation wicri:level="3"><nlm:affiliation>Dyslipidemia and Atherosclerosis Research Unit, INSERM UMR-S939, and University of Pierre and Marie Curie, Pitie-Salpetriere University Hospital, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Dyslipidemia and Atherosclerosis Research Unit, INSERM UMR-S939, and University of Pierre and Marie Curie, Pitie-Salpetriere University Hospital, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2015">2015</date><idno type="RBID">pubmed:26486974</idno><idno type="pmid">26486974</idno><idno type="doi">10.1194/jlr.P061143</idno><idno type="wicri:Area/PubMed/Corpus">002615</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002615</idno><idno type="wicri:Area/PubMed/Curation">002546</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002546</idno><idno type="wicri:Area/PubMed/Checkpoint">002546</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002546</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Statin action favors normalization of the plasma lipidome in the atherogenic mixed dyslipidemia of MetS: potential relevance to statin-associated dysglycemia.</title><author><name sortKey="Meikle, Peter J" sort="Meikle, Peter J" uniqKey="Meikle P" first="Peter J" last="Meikle">Peter J. Meikle</name><affiliation wicri:level="3"><nlm:affiliation>Baker IDI Heart and Diabetes Institute, Melbourne, Australia peter.meikle@bakeridi.edu.au.</nlm:affiliation><country wicri:rule="url">Australie</country><wicri:regionArea>Baker IDI Heart and Diabetes Institute, Melbourne</wicri:regionArea><placeName><settlement type="city">Melbourne</settlement><region type="état">Victoria (État)</region></placeName></affiliation></author><author><name sortKey="Wong, Gerard" sort="Wong, Gerard" uniqKey="Wong G" first="Gerard" last="Wong">Gerard Wong</name><affiliation wicri:level="3"><nlm:affiliation>Baker IDI Heart and Diabetes Institute, Melbourne, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Baker IDI Heart and Diabetes Institute, Melbourne</wicri:regionArea><placeName><settlement type="city">Melbourne</settlement><region type="état">Victoria (État)</region></placeName></affiliation></author><author><name sortKey="Tan, Ricardo" sort="Tan, Ricardo" uniqKey="Tan R" first="Ricardo" last="Tan">Ricardo Tan</name><affiliation wicri:level="3"><nlm:affiliation>Baker IDI Heart and Diabetes Institute, Melbourne, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Baker IDI Heart and Diabetes Institute, Melbourne</wicri:regionArea><placeName><settlement type="city">Melbourne</settlement><region type="état">Victoria (État)</region></placeName></affiliation></author><author><name sortKey="Giral, Philippe" sort="Giral, Philippe" uniqKey="Giral P" first="Philippe" last="Giral">Philippe Giral</name><affiliation wicri:level="3"><nlm:affiliation>Dyslipidemia and Atherosclerosis Research Unit, INSERM UMR-S939, and University of Pierre and Marie Curie, Pitie-Salpetriere University Hospital, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Dyslipidemia and Atherosclerosis Research Unit, INSERM UMR-S939, and University of Pierre and Marie Curie, Pitie-Salpetriere University Hospital, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Robillard, Paul" sort="Robillard, Paul" uniqKey="Robillard P" first="Paul" last="Robillard">Paul Robillard</name><affiliation wicri:level="3"><nlm:affiliation>Dyslipidemia and Atherosclerosis Research Unit, INSERM UMR-S939, and University of Pierre and Marie Curie, Pitie-Salpetriere University Hospital, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Dyslipidemia and Atherosclerosis Research Unit, INSERM UMR-S939, and University of Pierre and Marie Curie, Pitie-Salpetriere University Hospital, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Orsoni, Alexina" sort="Orsoni, Alexina" uniqKey="Orsoni A" first="Alexina" last="Orsoni">Alexina Orsoni</name><affiliation wicri:level="3"><nlm:affiliation>Dyslipidemia and Atherosclerosis Research Unit, INSERM UMR-S939, and University of Pierre and Marie Curie, Pitie-Salpetriere University Hospital, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Dyslipidemia and Atherosclerosis Research Unit, INSERM UMR-S939, and University of Pierre and Marie Curie, Pitie-Salpetriere University Hospital, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Hounslow, Neil" sort="Hounslow, Neil" uniqKey="Hounslow N" first="Neil" last="Hounslow">Neil Hounslow</name><affiliation wicri:level="1"><nlm:affiliation>Kowa Research Europe Ltd., Wokingham, United Kingdom.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Kowa Research Europe Ltd., Wokingham</wicri:regionArea><wicri:noRegion>Wokingham</wicri:noRegion></affiliation></author><author><name sortKey="Magliano, Dianna J" sort="Magliano, Dianna J" uniqKey="Magliano D" first="Dianna J" last="Magliano">Dianna J. Magliano</name><affiliation wicri:level="3"><nlm:affiliation>Baker IDI Heart and Diabetes Institute, Melbourne, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Baker IDI Heart and Diabetes Institute, Melbourne</wicri:regionArea><placeName><settlement type="city">Melbourne</settlement><region type="état">Victoria (État)</region></placeName></affiliation></author><author><name sortKey="Shaw, Jonathan E" sort="Shaw, Jonathan E" uniqKey="Shaw J" first="Jonathan E" last="Shaw">Jonathan E. Shaw</name><affiliation wicri:level="3"><nlm:affiliation>Baker IDI Heart and Diabetes Institute, Melbourne, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Baker IDI Heart and Diabetes Institute, Melbourne</wicri:regionArea><placeName><settlement type="city">Melbourne</settlement><region type="état">Victoria (État)</region></placeName></affiliation></author><author><name sortKey="Curran, Joanne E" sort="Curran, Joanne E" uniqKey="Curran J" first="Joanne E" last="Curran">Joanne E. Curran</name><affiliation wicri:level="2"><nlm:affiliation>South Texas Diabetes and Obesity Institute, University of Texas Health Science Center at San Antonio, Harlingen, TX.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Texas</region></placeName><wicri:cityArea>South Texas Diabetes and Obesity Institute, University of Texas Health Science Center at San Antonio, Harlingen</wicri:cityArea></affiliation></author><author><name sortKey="Blangero, John" sort="Blangero, John" uniqKey="Blangero J" first="John" last="Blangero">John Blangero</name><affiliation wicri:level="2"><nlm:affiliation>South Texas Diabetes and Obesity Institute, University of Texas Health Science Center at San Antonio, Harlingen, TX.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Texas</region></placeName><wicri:cityArea>South Texas Diabetes and Obesity Institute, University of Texas Health Science Center at San Antonio, Harlingen</wicri:cityArea></affiliation></author><author><name sortKey="Kingwell, Bronwyn A" sort="Kingwell, Bronwyn A" uniqKey="Kingwell B" first="Bronwyn A" last="Kingwell">Bronwyn A. Kingwell</name><affiliation wicri:level="3"><nlm:affiliation>Baker IDI Heart and Diabetes Institute, Melbourne, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Baker IDI Heart and Diabetes Institute, Melbourne</wicri:regionArea><placeName><settlement type="city">Melbourne</settlement><region type="état">Victoria (État)</region></placeName></affiliation></author><author><name sortKey="Chapman, M John" sort="Chapman, M John" uniqKey="Chapman M" first="M John" last="Chapman">M John Chapman</name><affiliation wicri:level="3"><nlm:affiliation>Dyslipidemia and Atherosclerosis Research Unit, INSERM UMR-S939, and University of Pierre and Marie Curie, Pitie-Salpetriere University Hospital, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Dyslipidemia and Atherosclerosis Research Unit, INSERM UMR-S939, and University of Pierre and Marie Curie, Pitie-Salpetriere University Hospital, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author></analytic><series><title level="j">Journal of lipid research</title><idno type="eISSN">1539-7262</idno><imprint><date when="2015" type="published">2015</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Aged</term><term>Atherosclerosis (blood)</term><term>Atherosclerosis (drug therapy)</term><term>Cholesterol</term><term>Cholesterol, HDL</term><term>Cholesterol, LDL</term><term>Dyslipidemias (blood)</term><term>Dyslipidemias (drug therapy)</term><term>Female</term><term>Glucose Metabolism Disorders (blood)</term><term>Glucose Metabolism Disorders (chemically induced)</term><term>Humans</term><term>Hydroxymethylglutaryl-CoA Reductase Inhibitors (therapeutic use)</term><term>Lipoproteins</term><term>Male</term><term>Metabolic Syndrome X (blood)</term><term>Metabolic Syndrome X (drug therapy)</term><term>Middle Aged</term><term>Triglycerides</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Athérosclérose (sang)</term><term>Athérosclérose (traitement médicamenteux)</term><term>Cholestérol</term><term>Cholestérol HDL</term><term>Cholestérol LDL</term><term>Dyslipidémies (sang)</term><term>Dyslipidémies (traitement médicamenteux)</term><term>Femelle</term><term>Humains</term><term>Inhibiteurs de l'hydroxyméthylglutaryl-CoA réductase (usage thérapeutique)</term><term>Lipoprotéines</term><term>Mâle</term><term>Sujet âgé</term><term>Syndrome métabolique X (sang)</term><term>Syndrome métabolique X (traitement médicamenteux)</term><term>Triglycéride</term><term>Troubles du métabolisme du glucose ()</term><term>Troubles du métabolisme du glucose (sang)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Hydroxymethylglutaryl-CoA Reductase Inhibitors</term></keywords><keywords scheme="MESH" type="chemical" xml:lang="en"><term>Cholesterol</term><term>Cholesterol, HDL</term><term>Cholesterol, LDL</term><term>Lipoproteins</term><term>Triglycerides</term></keywords><keywords scheme="MESH" qualifier="blood" xml:lang="en"><term>Atherosclerosis</term><term>Dyslipidemias</term><term>Glucose Metabolism Disorders</term><term>Metabolic Syndrome X</term></keywords><keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Glucose Metabolism Disorders</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Atherosclerosis</term><term>Dyslipidemias</term><term>Metabolic Syndrome X</term></keywords><keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Athérosclérose</term><term>Dyslipidémies</term><term>Syndrome métabolique X</term><term>Troubles du métabolisme du glucose</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Athérosclérose</term><term>Dyslipidémies</term><term>Syndrome métabolique X</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Inhibiteurs de l'hydroxyméthylglutaryl-CoA réductase</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Cholestérol</term><term>Cholestérol HDL</term><term>Cholestérol LDL</term><term>Femelle</term><term>Humains</term><term>Lipoprotéines</term><term>Mâle</term><term>Sujet âgé</term><term>Triglycéride</term><term>Troubles du métabolisme du glucose</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The impact of statin treatment on the abnormal plasma lipidome of mixed dyslipidemic patients with metabolic syndrome (MetS), a group at increased risk of developing diabetes, was evaluated. Insulin-resistant hypertriglyceridemic hypertensive obese males (n = 12) displaying MetS were treated with pitavastatin (4 mg/day) for 180 days; healthy normolipidemic age-matched nonobese males (n = 12) acted as controls. Statin treatment substantially normalized triglyceride (-41%), remnant cholesterol (-55%), and LDL-cholesterol (-39%), with minor effect on HDL-cholesterol (+4%). Lipidomic analysis, normalized to nonHDL-cholesterol in order to probe statin-induced differences in molecular composition independently of reduction in plasma cholesterol, revealed increment in 132 of 138 lipid species that were subnormal at baseline and significantly shifted toward the control group on statin treatment. Increment in alkyl- and alkenylphospholipids (plasmalogens) was prominent, and consistent with significant statin-induced increase in plasma polyunsaturated fatty acid levels. Comparison of the statin-mediated lipidomic changes in MetS with the abnormal plasma lipidomic profile characteristic of prediabetes and T2D in the Australian Diabetes, Obesity, and Lifestyle Study and San Antonio Family Heart Study cohorts by hypergeometric analysis revealed a significant shift toward the lipid profile of controls, indicative of a marked trend toward a normolipidemic phenotype. Pitavastatin attenuated the abnormal plasma lipidome of MetS patients typical of prediabetes and T2D.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">26486974</PMID><DateCreated><Year>2015</Year><Month>12</Month><Day>02</Day></DateCreated><DateCompleted><Year>2016</Year><Month>09</Month><Day>23</Day></DateCompleted><DateRevised><Year>2017</Year><Month>11</Month><Day>16</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1539-7262</ISSN><JournalIssue CitedMedium="Internet"><Volume>56</Volume><Issue>12</Issue><PubDate><Year>2015</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Journal of lipid research</Title><ISOAbbreviation>J. Lipid Res.</ISOAbbreviation></Journal><ArticleTitle>Statin action favors normalization of the plasma lipidome in the atherogenic mixed dyslipidemia of MetS: potential relevance to statin-associated dysglycemia.</ArticleTitle><Pagination><MedlinePgn>2381-92</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1194/jlr.P061143</ELocationID><Abstract><AbstractText>The impact of statin treatment on the abnormal plasma lipidome of mixed dyslipidemic patients with metabolic syndrome (MetS), a group at increased risk of developing diabetes, was evaluated. Insulin-resistant hypertriglyceridemic hypertensive obese males (n = 12) displaying MetS were treated with pitavastatin (4 mg/day) for 180 days; healthy normolipidemic age-matched nonobese males (n = 12) acted as controls. Statin treatment substantially normalized triglyceride (-41%), remnant cholesterol (-55%), and LDL-cholesterol (-39%), with minor effect on HDL-cholesterol (+4%). Lipidomic analysis, normalized to nonHDL-cholesterol in order to probe statin-induced differences in molecular composition independently of reduction in plasma cholesterol, revealed increment in 132 of 138 lipid species that were subnormal at baseline and significantly shifted toward the control group on statin treatment. Increment in alkyl- and alkenylphospholipids (plasmalogens) was prominent, and consistent with significant statin-induced increase in plasma polyunsaturated fatty acid levels. Comparison of the statin-mediated lipidomic changes in MetS with the abnormal plasma lipidomic profile characteristic of prediabetes and T2D in the Australian Diabetes, Obesity, and Lifestyle Study and San Antonio Family Heart Study cohorts by hypergeometric analysis revealed a significant shift toward the lipid profile of controls, indicative of a marked trend toward a normolipidemic phenotype. Pitavastatin attenuated the abnormal plasma lipidome of MetS patients typical of prediabetes and T2D.</AbstractText><CopyrightInformation>Copyright © 2015 by the American Society for Biochemistry and Molecular Biology, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Meikle</LastName><ForeName>Peter J</ForeName><Initials>PJ</Initials><AffiliationInfo><Affiliation>Baker IDI Heart and Diabetes Institute, Melbourne, Australia peter.meikle@bakeridi.edu.au.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wong</LastName><ForeName>Gerard</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Baker IDI Heart and Diabetes Institute, Melbourne, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tan</LastName><ForeName>Ricardo</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Baker IDI Heart and Diabetes Institute, Melbourne, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Giral</LastName><ForeName>Philippe</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Dyslipidemia and Atherosclerosis Research Unit, INSERM UMR-S939, and University of Pierre and Marie Curie, Pitie-Salpetriere University Hospital, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Robillard</LastName><ForeName>Paul</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Dyslipidemia and Atherosclerosis Research Unit, INSERM UMR-S939, and University of Pierre and Marie Curie, Pitie-Salpetriere University Hospital, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Orsoni</LastName><ForeName>Alexina</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Dyslipidemia and Atherosclerosis Research Unit, INSERM UMR-S939, and University of Pierre and Marie Curie, Pitie-Salpetriere University Hospital, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hounslow</LastName><ForeName>Neil</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Kowa Research Europe Ltd., Wokingham, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Magliano</LastName><ForeName>Dianna J</ForeName><Initials>DJ</Initials><AffiliationInfo><Affiliation>Baker IDI Heart and Diabetes Institute, Melbourne, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shaw</LastName><ForeName>Jonathan E</ForeName><Initials>JE</Initials><AffiliationInfo><Affiliation>Baker IDI Heart and Diabetes Institute, Melbourne, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Curran</LastName><ForeName>Joanne E</ForeName><Initials>JE</Initials><AffiliationInfo><Affiliation>South Texas Diabetes and Obesity Institute, University of Texas Health Science Center at San Antonio, Harlingen, TX.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blangero</LastName><ForeName>John</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>South Texas Diabetes and Obesity Institute, University of Texas Health Science Center at San Antonio, Harlingen, TX.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kingwell</LastName><ForeName>Bronwyn A</ForeName><Initials>BA</Initials><AffiliationInfo><Affiliation>Baker IDI Heart and Diabetes Institute, Melbourne, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chapman</LastName><ForeName>M John</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Dyslipidemia and Atherosclerosis Research Unit, INSERM UMR-S939, and University of Pierre and Marie Curie, Pitie-Salpetriere University Hospital, Paris, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT01595828</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>R01 DK088972</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>1R01DK088972-01</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>10</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Lipid Res</MedlineTA><NlmUniqueID>0376606</NlmUniqueID><ISSNLinking>0022-2275</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008076">Cholesterol, HDL</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008078">Cholesterol, LDL</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019161">Hydroxymethylglutaryl-CoA Reductase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008074">Lipoproteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014280">Triglycerides</NameOfSubstance></Chemical><Chemical><RegistryNumber>97C5T2UQ7J</RegistryNumber><NameOfSubstance UI="D002784">Cholesterol</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>Diabetologia. 2009 Dec;52(12):2612-5</RefSource><PMID Version="1">19669729</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Lipid Res. 2011 Feb;52(2):399-407</RefSource><PMID Version="1">21068006</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Atherosclerosis. 2014 Mar;233(1):130-8</RefSource><PMID Version="1">24529133</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Lipid Res. 2010 Jun;51(6):1546-53</RefSource><PMID Version="1">19965573</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lipids Health Dis. 2010;9:62</RefSource><PMID Version="1">20546600</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Arterioscler Thromb Vasc Biol. 2011 Nov;31(11):2723-32</RefSource><PMID Version="1">21903946</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Endocrinol Metab. 2004 Oct;89(10):4963-71</RefSource><PMID Version="1">15472192</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Eur Heart J. 2011 Jul;32(14):1769-818</RefSource><PMID Version="1">21712404</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Eur Heart J. 2010 Jan;31(2):149-64</RefSource><PMID Version="1">19825813</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Eur Heart J. 2011 Jun;32(11):1345-61</RefSource><PMID Version="1">21531743</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Lipid Res. 2013 Oct;54(10):2898-908</RefSource><PMID Version="1">23868910</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Pharmacol Ther. 2014 Jul;143(1):12-23</RefSource><PMID Version="1">24509229</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>BMC Endocr Disord. 2013 Oct 16;13:47</RefSource><PMID Version="1">24131857</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Diabetes. 2013 Feb;62(2):401-10</RefSource><PMID Version="1">23139352</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet. 2010 Nov 13;376(9753):1670-81</RefSource><PMID Version="1">21067804</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Circulation. 1996 Nov 1;94(9):2159-70</RefSource><PMID Version="1">8901667</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Chem Phys Lipids. 1995 Aug 1;77(1):25-31</RefSource><PMID Version="1">7586089</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Circulation. 2006 Dec 19;114(25):2788-97</RefSource><PMID Version="1">17159064</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Diabetologia. 2015 May;58(5):1109-17</RefSource><PMID Version="1">25754552</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Circ Cardiovasc Qual Outcomes. 2013 Jul;6(4):390-9</RefSource><PMID Version="1">23838105</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Arterioscler Thromb Vasc Biol. 2003 Oct 1;23(10):1881-8</RefSource><PMID Version="1">12920049</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Diabetes Res Clin Pract. 2002 Aug;57(2):119-29</RefSource><PMID Version="1">12062857</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Biochim Biophys Acta. 2013 Mar;1831(3):626-32</RefSource><PMID Version="1">22877991</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Arterioscler Thromb Vasc Biol. 2009 Dec;29(12):2169-75</RefSource><PMID Version="1">19762782</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Arterioscler Thromb Vasc Biol. 2007 Aug;27(8):1843-9</RefSource><PMID Version="1">17569880</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet. 2012 Aug 11;380(9841):565-71</RefSource><PMID Version="1">22883507</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cell Metab. 2014 Nov 4;20(5):787-98</RefSource><PMID Version="1">25444678</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Atheroscler Suppl. 2014 Jun;15(1):1-15</RefSource><PMID Version="1">24840509</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet. 2015 Jan 24;385(9965):351-61</RefSource><PMID Version="1">25262344</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Curr Med Res Opin. 2014 May;30(5):775-84</RefSource><PMID Version="1">24328357</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Atherosclerosis. 2015 Aug;241(2):409-18</RefSource><PMID Version="1">26074315</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Am J Cardiol. 2013 Apr 15;111(8):1123-30</RefSource><PMID Version="1">23352266</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Acta Physiol Scand. 2002 Dec;176(4):263-8</RefSource><PMID Version="1">12444931</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Am J Epidemiol. 2006 May 15;163(10):903-12</RefSource><PMID Version="1">16611667</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Circulation. 2015 Mar 3;131(9):774-85</RefSource><PMID Version="1">25573147</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Arterioscler Thromb Vasc Biol. 2002 Oct 1;22(10):1524-34</RefSource><PMID Version="1">12377727</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Arterioscler Thromb Vasc Biol. 1997 Nov;17(11):2685-91</RefSource><PMID Version="1">9409243</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2011 Dec 1;365(22):2078-87</RefSource><PMID Version="1">22085316</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>PLoS One. 2013;8(9):e74341</RefSource><PMID Version="1">24086336</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Biochim Biophys Acta. 2013 Nov;1831(11):1609-17</RefSource><PMID Version="1">23896361</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Am Coll Cardiol. 2013 Jan 15;61(2):148-52</RefSource><PMID Version="1">23219296</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D050197" MajorTopicYN="N">Atherosclerosis</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002784" MajorTopicYN="N">Cholesterol</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008076" MajorTopicYN="N">Cholesterol, HDL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008078" MajorTopicYN="N">Cholesterol, LDL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D050171" MajorTopicYN="N">Dyslipidemias</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D044882" MajorTopicYN="N">Glucose Metabolism Disorders</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019161" MajorTopicYN="N">Hydroxymethylglutaryl-CoA Reductase Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008074" MajorTopicYN="N">Lipoproteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D024821" MajorTopicYN="N">Metabolic Syndrome X</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014280" MajorTopicYN="N">Triglycerides</DescriptorName></MeshHeading></MeshHeadingList><OtherID Source="NLM">PMC4655992 [Available on 12/01/16]</OtherID><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">cholesterol</Keyword><Keyword MajorTopicYN="N">lipidomics</Keyword><Keyword MajorTopicYN="N">metabolic syndrome</Keyword><Keyword MajorTopicYN="N">obesity</Keyword><Keyword MajorTopicYN="N">omega-3 fatty acids</Keyword><Keyword MajorTopicYN="N">pitavastatin</Keyword><Keyword MajorTopicYN="N">plasmalogens</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>06</Month><Day>03</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>10</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>10</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>9</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26486974</ArticleId><ArticleId IdType="pii">jlr.P061143</ArticleId><ArticleId IdType="doi">10.1194/jlr.P061143</ArticleId><ArticleId IdType="pmc">PMC4655992</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Australie</li><li>France</li><li>Royaume-Uni</li><li>États-Unis</li></country><region><li>Texas</li><li>Victoria (État)</li><li>Île-de-France</li></region><settlement><li>Melbourne</li><li>Paris</li></settlement></list><tree><country name="Australie"><region name="Victoria (État)"><name sortKey="Meikle, Peter J" sort="Meikle, Peter J" uniqKey="Meikle P" first="Peter J" last="Meikle">Peter J. Meikle</name></region><name sortKey="Kingwell, Bronwyn A" sort="Kingwell, Bronwyn A" uniqKey="Kingwell B" first="Bronwyn A" last="Kingwell">Bronwyn A. Kingwell</name><name sortKey="Magliano, Dianna J" sort="Magliano, Dianna J" uniqKey="Magliano D" first="Dianna J" last="Magliano">Dianna J. Magliano</name><name sortKey="Shaw, Jonathan E" sort="Shaw, Jonathan E" uniqKey="Shaw J" first="Jonathan E" last="Shaw">Jonathan E. Shaw</name><name sortKey="Tan, Ricardo" sort="Tan, Ricardo" uniqKey="Tan R" first="Ricardo" last="Tan">Ricardo Tan</name><name sortKey="Wong, Gerard" sort="Wong, Gerard" uniqKey="Wong G" first="Gerard" last="Wong">Gerard Wong</name></country><country name="France"><region name="Île-de-France"><name sortKey="Giral, Philippe" sort="Giral, Philippe" uniqKey="Giral P" first="Philippe" last="Giral">Philippe Giral</name></region><name sortKey="Chapman, M John" sort="Chapman, M John" uniqKey="Chapman M" first="M John" last="Chapman">M John Chapman</name><name sortKey="Orsoni, Alexina" sort="Orsoni, Alexina" uniqKey="Orsoni A" first="Alexina" last="Orsoni">Alexina Orsoni</name><name sortKey="Robillard, Paul" sort="Robillard, Paul" uniqKey="Robillard P" first="Paul" last="Robillard">Paul Robillard</name></country><country name="Royaume-Uni"><noRegion><name sortKey="Hounslow, Neil" sort="Hounslow, Neil" uniqKey="Hounslow N" first="Neil" last="Hounslow">Neil Hounslow</name></noRegion></country><country name="États-Unis"><region name="Texas"><name sortKey="Curran, Joanne E" sort="Curran, Joanne E" uniqKey="Curran J" first="Joanne E" last="Curran">Joanne E. Curran</name></region><name sortKey="Blangero, John" sort="Blangero, John" uniqKey="Blangero J" first="John" last="Blangero">John Blangero</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002649 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 002649 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:26486974
|texte= Statin action favors normalization of the plasma lipidome in the atherogenic mixed dyslipidemia of MetS: potential relevance to statin-associated dysglycemia.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:26486974" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |